Yin Junwei, Zhao Yongli, Yin Junping, Yang Shanshan
Department of Interventional, The First Affiliated Hospital of Xinxiang Medical University, No.88, Health Road, Weihui, Xinxiang, 453100, Henan Province, China.
Obstetrics and Gynecology, Tongxu Traditional Chinese Medicine Hospital Tongxu City, Kaifeng City, 475400, Henan Province, China.
Clin Transl Oncol. 2025 Mar 5. doi: 10.1007/s12094-025-03879-0.
Liver metastases from colorectal cancer are a common and serious complication that significantly impacts patient survival. The aim of this study is to investigate the clinical efficacy of transarterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in the treatment of liver metastases from colorectal cancer.
A retrospective analysis was conducted on 120 patients with liver metastases from colorectal cancer who were treated in our hospital from January 2018 to January 2023. The patients were divided into two groups based on the treatment they received: the TACE group (n = 60) and the TACE combined with RFA group (n = 60). The overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were compared between the two groups, and treatment-related adverse effects were recorded.
The TACE combined with RFA group showed significantly better OS (22 months vs. 18 months) and PFS (13 months vs. 10 months) compared to the TACE alone group (P < 0.05). The ORR in the TACE combined with RFA group was 61.7%, significantly higher than 40% in the TACE alone group (P < 0.05). The DCR showed no significant difference between the two groups, with 86.7% (52/60) in the TACE combined with RFA group and 78.3% (47/60) in the TACE alone group (P > 0.05). There were no significant differences in treatment-related adverse effects between the two groups (P > 0.05).
These findings suggest that TACE combined with RFA may offer a potential option for improving OS, PFS, and ORR in patients with liver metastases from colorectal cancer, without increasing significant adverse effects, setting a new potential standard of care in the treatment of this disease.
结直肠癌肝转移是一种常见且严重的并发症，对患者生存有显著影响。本研究旨在探讨经动脉化疗栓塞术（TACE）联合射频消融术（RFA）治疗结直肠癌肝转移的临床疗效。
对2018年1月至2023年1月在我院接受治疗的120例结直肠癌肝转移患者进行回顾性分析。根据所接受的治疗将患者分为两组：TACE组（n = 60）和TACE联合RFA组（n = 60）。比较两组的总生存期（OS）、无进展生存期（PFS）、客观缓解率（ORR）和疾病控制率（DCR），并记录治疗相关不良反应。
与单纯TACE组相比，TACE联合RFA组的OS（22个月对18个月）和PFS（13个月对10个月）显著更好（P < 0.05）。TACE联合RFA组的ORR为61.7%，显著高于单纯TACE组的40%（P < 0.05）。两组的DCR无显著差异，TACE联合RFA组为86.7%（52/60），单纯TACE组为78.3%（47/60）（P > 0.05）。两组治疗相关不良反应无显著差异（P > 0.05）。
这些结果表明，TACE联合RFA可能为改善结直肠癌肝转移患者的OS、PFS和ORR提供一种潜在选择，且不增加显著不良反应，为该疾病的治疗设定了新的潜在护理标准。
